These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36997073)

  • 1. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
    Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
    Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
    Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
    Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
    J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir.
    Lin C; Jiang H; Li W; Zeng P; Zhou X; Zhang J; Li J
    Structure; 2023 Sep; 31(9):1016-1024.e3. PubMed ID: 37421945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
    Akaji K; Konno H
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
    Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
    Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
    Stefanelli I; Corona A; Cerchia C; Cassese E; Improta S; Costanzi E; Pelliccia S; Morasso S; Esposito F; Paulis A; Scognamiglio S; Di Leva FS; Storici P; Brindisi M; Tramontano E; Cannalire R; Summa V
    Eur J Med Chem; 2023 May; 253():115311. PubMed ID: 37043904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
    Brier L; Hassan H; Hanoulle X; Landry V; Moschidi D; Desmarets L; Rouillé Y; Dumont J; Herledan A; Warenghem S; Piveteau C; Carré P; Ikherbane S; Cantrelle FX; Dupré E; Dubuisson J; Belouzard S; Leroux F; Deprez B; Charton J
    Eur J Med Chem; 2023 Mar; 250():115186. PubMed ID: 36796300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
    Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
    Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
    Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
    Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
    Wang H; Pei R; Li X; Deng W; Xing S; Zhang Y; Zhang C; He S; Sun H; Xiao S; Xiong J; Zhang Y; Chen X; Wang Y; Guo Y; Zhang B; Shang L
    Eur J Med Chem; 2022 Aug; 238():114458. PubMed ID: 35635946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors.
    He J; Hu L; Huang X; Wang C; Zhang Z; Wang Y; Zhang D; Ye W
    Int J Antimicrob Agents; 2020 Aug; 56(2):106055. PubMed ID: 32534187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
    Xiong M; Nie T; Shao Q; Li M; Su H; Xu Y
    Eur J Med Chem; 2022 Mar; 231():114130. PubMed ID: 35114541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.
    Liu H; Iketani S; Zask A; Khanizeman N; Bednarova E; Forouhar F; Fowler B; Hong SJ; Mohri H; Nair MS; Huang Y; Tay NES; Lee S; Karan C; Resnick SJ; Quinn C; Li W; Shion H; Xia X; Daniels JD; Bartolo-Cruz M; Farina M; Rajbhandari P; Jurtschenko C; Lauber MA; McDonald T; Stokes ME; Hurst BL; Rovis T; Chavez A; Ho DD; Stockwell BR
    Nat Commun; 2022 Apr; 13(1):1891. PubMed ID: 35393402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL
    Ma L; Li Q; Xie Y; Jianyuan Zhao ; Yi D; Guo S; Guo F; Wang J; Yang L; Cen S
    Antiviral Res; 2022 Nov; 207():105419. PubMed ID: 36155070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.
    Jiang X; Su H; Shang W; Zhou F; Zhang Y; Zhao W; Zhang Q; Xie H; Jiang L; Nie T; Yang F; Xiong M; Huang X; Li M; Chen P; Peng S; Xiao G; Jiang H; Tang R; Zhang L; Shen J; Xu Y
    Nat Commun; 2023 Oct; 14(1):6463. PubMed ID: 37833261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulforaphane is a reversible covalent inhibitor of 3-chymotrypsin-like protease of SARS-CoV-2.
    Chen Z; Du R; Cooper L; Achi JG; Dong M; Ran Y; Zhang J; Zhan P; Rong L; Cui Q
    J Med Virol; 2023 Mar; 95(3):e28609. PubMed ID: 36840402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.